Navigation Links
Quest Diagnostics Reports Growth in Revenue and Earnings for Fourth Quarter 2008 and Provides 2009 Guidance
Date:1/26/2009

million reserve established for the previously disclosed NID matter, or approximately $700 million after such payment. Capital expenditures are expected to approximate $200 million.

Quest Diagnostics will hold its fourth quarter conference call on January 26, 2009 at 8:30 A.M. Eastern Time. A simulcast of the call is available by dialing 415-228-4961, passcode 3214469 and via the Internet at: www.questdiagnostics.com. Registered analysts may access the call at: www.streetevents.com. In addition, a replay of the call will be available from 10:30 A.M. on January 26 through midnight on February 23, 2009 to investors in the U.S. by dialing 866-431-7950. Investors outside the U.S. may dial 203-369-0981. No password is required for either number.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care.

Quest Diagnostics maintains one of the largest private clinical laboratory databases in the United States. The data is used to generate Quest Diagnostics Health Trends(TM), which identifies and tracks disease and wellness benchmarks, and the Drug Testing Index(R), which is published as a public service for government, media and industry and has been considered a benchmark for national drugs-of-abuse trends since its inception in 1988. Additional company information is available at
'/>"/>

SOURCE Quest Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Quest Diagnostics Board Authorizes $500 Million in Share Repurchases
2. First Study to Test Real-World Effects of Stun Gun Use Raises Questions about Safety
3. Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
4. Xmark Sends Letters to Icagens Board of Directors: Questions Companys Leadership as Well as Motives Behind Adoption of Poison Pill
5. Quest Diagnostics to Release Fourth Quarter and Full Year 2008 Financial Results
6. Study of Everest Climbers Questions Oxygen Use
7. Inside out Applesauce Fueling Oklahomas Title Quest
8. U.S. Navy Requested Operations Trial on FDA Hold
9. A simple questionnaire to replace a doctors exam
10. Allsup Outlines 10 Essential Questions People Need to Ask when Evaluating Medicare Plans
11. Hospice Community Encouraged to Respond to Daschle Request to Participate in Information Gathering about Healthcare Concerns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... The establishment and creation of ... one of the main strategies of the Church ... impact around the world. , Architecturally stellar buildings ... executives and trainers deliver L. Ron Hubbard's spiritual ... statistics demonstrate that significant reduction in crime, major ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all things senior, ... Disease, Dementia, and Memory Loss . , Country singer Glen ... with the Alzheimer’s, inspired Seniors Guide writers to review the ... movie, out on October 14, 2014, shows a glimpse of ... disease – which inspires a final tour from the musician ...
(Date:8/30/2014)... By Randy Dotinga ... -- About one in five patients operated on for broken ... after surgery, a new study finds. Less-educated patients ... times more likely to be "doctor shoppers," said study lead ... Lexington, Ky. Overall, he said, the study suggests that doctors ...
(Date:8/30/2014)... commonly used to treat gout, before and after ... complications from this type of surgery, but it ... according to a study published by JAMA ... to coincide with its presentation at the European ... cardiac surgery include postpericardiotomy syndrome (the occurrence of ...
(Date:8/30/2014)... Bringing forth the great opportunities, India's #1 ... Day discount on all SEO services. While working with ... related to internet marketing. Their dedicated team of professionals ... have a deep understanding for their specialization. This further ... since the inception, they have worked with over 5000 ...
Breaking Medicine News(10 mins):Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2
... ARLINGTON, Va., Nov. 16 Acknowledging that their results ... in the International Journal of Andrology nevertheless attempt to link ... to maternal exposure to phthalates. The researchers, led by ... previous, and much publicized, study of phthalate exposure to evaluate ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 15 ... Company will hold a teleconference and webcast at 8:00 a.m. Eastern ... Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of ... Conference Call and Webcast Information , To participate ...
... 15 The World Champion New York Yankees ... at New York Blood Center,s (NYBC) Biennial Chairman,s Dinner this ... The event is chaired by William J. Mullaney, MetLife ... the opportunity to honor these two outstanding supporting organizations as ...
... ... its intention to begin the drug registration process in Brazil and Colombia for its ... United States for the treatment of moderate to severe (Stage 2) chronic pain. ... Plantation, FL (Vocus) ...
... , ... from the RecordAF,registry (REgistry on Cardiac rhythm disORDers assessing ... Sessions of the,American Heart Association, show that in recently ... rhythm-control strategy,provides better short term control of the arrhythmia ...
... when new lead is needed in heart devices, ... -- Replacing or adding wiring increases the risk ... replace a pacemaker or other heart rhythm-stabilizing device, ... complication rates among patients enrolled in the REPLACE ...
Cached Medicine News:Health News:Swan Study Authors Note Results 'Not Straightforward' 2Health News:Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer 2Health News:World Champion New York Yankees, BNY Mellon to be Honored as New York Blood Center 'Champions of Life' 2Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 2Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 3Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 4Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 2Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 3Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 4Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 5
(Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... September 15 NicOx S.A. (Euronext,Paris: COX) today ... study for naproxcinod in 1020 patients with osteoarthritis ... naproxcinod (750 mg and 375 mg bid) met,the ... study,also comfortably met the main secondary endpoint, demonstrating ...
... ... Osteoarthritis, WALTHAM, ... announced today that Kenneth Kornman, Ph.D.,the company,s Chief Scientific Officer, ... (OA) at the 2008 World Congress,on Osteoarthritis, sponsored by the ...
Cached Medicine Technology:NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 2NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 3NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 4NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 5Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis 2Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis 3Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis 4
... to having been designed exclusively for vascular treatments, ... the Smartepil range which ensures fast amortisation of ... systems, it can be fitted with a polarised ... the target to be treated as well as ...
... SmartLite Derm is a KTP laser, ... of 532 nm (frequency doubled Nd:YAG) for ... by the comfortable color LCD Touch-screen. ... available are 0.3, 0.5, 0.7 and 1.0 ...
... a new and powerful instrument for ... system (MEL @308 nm - UVB) ... vitiligo. Designed to treat recalcitrant plaques, ... exposure of extensive lesions without irradiating ...
... a CO2 laser system with CW intensities ... dealing with all therapeutic application in modern ... medium-to-high intensities in super-pulsed mode, designed for ... It is also capable of supplying soft ...
Medicine Products: